/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company has a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly mat…
$1.20
$0.12 (-9.09%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-103.60% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 12.5% YoY with margins expanding 11.5pp.
ROIC dropped from -296.32% to -421.07%, capital efficiency is deteriorating. Negative free cash flow of -$741K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$7M
▲ +12.5% YoY
Net Income (TTM)
-$4M
▼ -17.3% YoY
Op. Margin
-59.10%
▲ +11.5pp YoY
ROIC
-322.24%
▼ -124.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$1M
▲ +48.9% YoY
Op. Cash Flow (TTM)
-$1M
▲ +50.5% YoY
Net Debt
-$1M
Net Cash Position
Cash & Equiv.
$2M
5Y CAGR: +11.2%
Continue Research
SourceComputed from the 10-Q filed 15 Jun 2026, covering the period ending 30 Apr 2026, as reported to the SEC. Data last refreshed 16 Jun 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Oct. Sector medians are approximate S&P 500 benchmarks and update periodically.
Zeo Scientifix (ZEOX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Zeo Scientifix scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Zeo Scientifix scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -59.1% operating margin and a -322.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ZEOX's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.